King & Spalding Continues Expansion of Its FDA/Healthcare Practice With Arrival of Partner Pam Furman and Consultants Ann Graham and Anne Kelly

WASHINGTON, DC -- (MARKET WIRE) -- February 6, 2007 -- In the continuing expansion of its FDA/Healthcare practice, King & Spalding, a leading international law firm, announced today the addition of partner Pamela J. Furman and consultants Ann Graham and Anne E. Kelly, whose special expertise enhances the firm's practice serving the pharmaceutical, biotechnology and medical device industries on FDA and healthcare regulatory issues. The arrival of these three women brings the total number of attorneys and non-attorney professionals in the practice to 35, making it the largest legal practice in the United States dedicated to the FDA and healthcare matters. This practice has more than doubled in size since 2004.

Furman, with a broad medical device practice that focuses on pre-market submissions and enforcement issues, joins King & Spalding's Washington, D.C. office as a partner. She will represent clients in areas including orthopedic, cardiovascular, surgical and dental devices. Furman was a principal at Olsson, Frank and Weeda, P.C.

Graham, as former branch chief of anesthesia and respiratory devices for the Office of Device Evaluation of the U.S. Food and Drug Administration, was responsible for review and approval of investigational device exemption applications as well as pre-market review and approval of these devices. At King & Spalding, she will specialize in the area of product submissions and medical devices, primarily for the medical device industry.

Anne E. Kelly, who recently served as senior vice president of quality for Andrx Pharmaceuticals, Inc., and is a former Midwest regional non-sterile drug expert and biologics specialist for the FDA's Chicago district office, will specialize in the area of quality systems, FDA product compliance standards and current good manufacturing practices for drugs, biologics and medical devices.

Both Kelly and Graham are based in the firm's Washington, D.C. office.

"We welcome Pam, Ann and Anne and look forward to the contributions they will make to our practice and our clients," said John T. Bentivoglio, co-head of King & Spalding's FDA/Healthcare practice. "We are proud of the work we do for our more than 500 life sciences clients, and we believe the addition of these newest members of our team will strengthen our reputation as the 'go to' law firm for medical devices."

More than 150 King & Spalding attorneys and non-attorney professionals devote all or a substantial portion of their practice to serving the firm's drug, device and biotech clients.

"For our pharmaceutical, medical device and biotech clients, getting top-notch counsel at every stage of the product life cycle is key," said Mark S. Brown, co-head of King & Spalding's FDA/Healthcare practice. "Pam, Ann and Anne add another dimension in our ability to do that by bringing us their special skills in FDA medical and regulatory issues."

Furman is nationally recognized for her work in medical devices and knowledge of FDA laws and regulations, specifically, pre-market submissions, quality system regulation compliance, recalls, medical device reporting, promotion and advertising, reclassification and import and export issues. She is vice chair for education programs of the Life Sciences Practice Group of the American Health Laws Association. She earned a B.A. degree in Political Science, summa cum laude, at Yale University and a J.D. degree at Stanford Law School.

Graham, an anaesthetist with 22 years' experience at the FDA, has focused on review of medical device pre-market submissions, technology assessments and setting standards for medical equipment manufacturers. She received an M.PH. in Epidemiology from Johns Hopkins University and a B.S. in Nursing from Northeastern University.

Kelly is a former FDA investigator, industry consultant on FDA compliance and vice president of quality with extensive experience in all aspects of current good manufacturing practices. She will assist the firm's clients in identifying potential CGMP problems and developing efficient and cost-effective solutions. She earned a B.S. in Medical Laboratory Science at the University of Illinois.

King & Spalding's Washington, D.C.-based FDA/Healthcare practice comprises 35 attorneys and non-attorney professionals who focus on assisting drug, device and biologics manufacturers at every stage of the product life cycle. The lawyers in this practice have expertise on a wide range of issues, including clinical development, FDA approval, CMA coverage and reimbursement, post-market advertising and promotion and healthcare regulatory compliance.

King & Spalding's Washington, D.C. office employs more than 160 attorneys and non-lawyer professionals, including government relations specialists, trade consultants and policy advisors. These lawyers and professionals practice in a broad range of areas including antitrust, class-action and mass tort litigation, commercial disputes, corporate finance, corporate governance, environmental, FDA/healthcare, public policy and government advocacy, government investigations, international trade, mergers and acquisitions and tax, among others.

About King & Spalding LLP

King & Spalding LLP is an international law firm with more than 800 lawyers in Atlanta, Dubai, Houston, London, New York and Washington, D.C. The firm represents half of the Fortune 100, and in a Corporate Counsel survey in August 2006 was ranked one of the top ten firms representing Fortune 250 companies overall. For additional information, visit http://www.kslaw.com/.

Contact Information: Contact: Jessica Schnack King & Spalding ph (212) 556-2226 Email Contact